Initial experience of robot-assisted breast conserving surgery for early breast cancer patients.

Authors

null

Se Hyun Paek

25, Magokdong-ro 2-gil, Gangseo-gu Seoul, Seoul, South Korea

Se Hyun Paek , Woosung Lim , Byung-In Moon

Organizations

25, Magokdong-ro 2-gil, Gangseo-gu Seoul, Seoul, South Korea, EUMC, Seoul, South Korea

Research Funding

No funding received
None.

Background: A traditional breast conserving surgery (BCS) operation inevitably results in an external scar on breast and axilla. Various attempts including endoscopy-assisted breast surgery has been successfully and reproducibly performed for improved cosmetic outcome. In an attempt to maximize esthetic effects, we performed robot-assisted BCS through only axillary incision. Methods: From Jan. 2021 to Dec. 2021, fifteen female patients underwent robot-assisted BCS. All patients underwent robot-assisted BCS with or without sentinel lymph node biopsy (SLNBx.) through only 2.5cm axillary incision. All surgical procedures were performed in concordance with traditional BCS operation. Data on patient demographics, type of surgery, hospital stay, complications, and short-term postoperative outcomes were reviewed. Results: Mean patient age was 53.7 ± 6.35 years and mean tumor size was 1.6 ± 2.1 cm. Indications included in situ cancer in 7 cases and invasive cancer in 8 cases. Three patients underwent only BCS, and twelve patients underwent BCS + SLNBx. Two patients underwent axillary lymph node dissection. The mean operation time was 165.5±8.2 minute and the mean hospital stay was 6.4 ± 5.3 days. No open conversion case was observed. One seroma with infection occurred postoperatively and I & D performed. Two skin burn event during operation was occurred and scar revision was performed. The operative scars in axilla became inconspicuous in a few weeks. Conclusions: Our initial results show that robot-assisted BCS would be technically feasible, safe, and effective. This new technique can be a good alternative surgical option for BCS in early breast cancer patients.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics

Sub Track

Other Technology and Innovations

Citation

JCO Global Oncology 9, 2023 (suppl 1; abstr 17)

DOI

10.1200/GO.2023.9.Supplement_1.17

Abstract #

17

Poster Bd #

C1

Abstract Disclosures

Similar Abstracts

First Author: Timothy Joseph Whelan

First Author: Tina Yi Jin Hsieh

Abstract

2023 ASCO Annual Meeting

Complicating breast cancer treatment: Reasons patients present to the ED.

First Author: Jayla Hsiung

First Author: Arun Kumar